Drug General Information
Drug ID
D00SDJ
Former ID
DNC006150
Drug Name
A-706149
Drug Type
Small molecular drug
Indication Discovery agent Investigative [527843]
Structure
Download
2D MOL

3D MOL

Formula
C27H34F3N5O2
Canonical SMILES
CC(C)(C)C1=NC(=CC(=N1)N2CCN(CC2)CCCCN3C(=O)CCC(=O)C4=CC<br />=CC=C43)C(F)(F)F
InChI
1S/C27H34F3N5O2/c1-26(2,3)25-31-22(27(28,29)30)18-23(32-25)34-16-14-33(15-17-34)12-6-7-13-35-20-9-5-4-8-19(20)21(36)10-11-24(35)37/h4-5,8-9,18H,6-7,10-17H2,1-3H3
InChIKey
FKHBHNWGBJHKGW-UHFFFAOYSA-N
PubChem Compound ID
Target and Pathway
Target(s) D(3) dopamine receptor Target Info Inhibitor [527843]
D(2) dopamine receptor Target Info Inhibitor [527843]
KEGG Pathway Neuroactive ligand-receptor interaction
Dopaminergic synapsehsa04015:Rap1 signaling pathway
cAMP signaling pathway
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholism
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
Reactome Dopamine receptors
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
G alpha (i) signalling events
WikiPathways Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic Neurons
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
Genes and (Common) Pathways Underlying Drug Addiction
References
Ref 527843Bioorg Med Chem Lett. 2006 Feb;16(3):658-62. Epub 2005 Nov 2.Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: Quinolin(di)one and benzazepin(di)one derivatives. herve.geneste@abbott.com.
Ref 527843Bioorg Med Chem Lett. 2006 Feb;16(3):658-62. Epub 2005 Nov 2.Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: Quinolin(di)one and benzazepin(di)one derivatives. herve.geneste@abbott.com.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.